 NEW YORK, Nov. 19, 2020 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for the treatment of diffuse intrinsic pontine glioma DIPG. Data was presented at the Society for Neuro-Oncology SNO Virtual Annual Meeting held November 19 through November 21, 2020. The omburtamab data was presented by Dr. Evan Bander from Weill Cornell Medicine. 